Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

150
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
150
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

112
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
112

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

No Evidence of QTc Interval Prolongation With Baxdrostat Treatment: Concentration-QTc Modeling Assessment.

Pharmacology research & perspectives·2025
Same author

Population Pharmacokinetic Analysis of Balcinrenone in Healthy Participants and Participants with Heart Failure and Chronic Kidney Disease.

Clinical pharmacokinetics·2025
Same author

A Case Study of Model-Informed Drug Development of a Novel PCSK9 Antisense Oligonucleotide. Part 2: Phase 2 to Phase 3.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Pharmacokinetic-pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus.

British journal of clinical pharmacology·2025
Same author

The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone.

British journal of clinical pharmacology·2025
Same author

Concentration-QT modeling demonstrates that the selective mineralocorticoid receptor modulator, balcinrenone (AZD9977), does not prolong QT interval.

CPT: pharmacometrics & systems pharmacology·2024
Same journal

Optimizing Subcutaneous Antibody Dosing Regimens Through Operating Space Maps: rHuPH20 Case Study.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Mechanistic modeling of FcRn-dependent IgG drug interactions: Clinical applications and dosing implications.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Comparing heavy-tailed residual error models for outlier handling in population PK modeling.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Personalized prophylactic therapy optimization in hemophilia A using a hybrid PK-PD-TTE model and deep RL.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Pediatric oral cavity physiologically based pharmacokinetic model to predict pharmacokinetics of mucoadhesive atropine gel to treat sialorrhea.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial.

Journal of pharmacokinetics and pharmacodynamics·2026
查看所有相关文章

相关实验视频

Updated: Sep 13, 2025

Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease
09:30

Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease

Published on: December 18, 2016

19.7K

集中度-QTc建模的实用指南:一个动手的教程.

Joanna Parkinson1, Corina Dota2, Dinko Rekić3,4

  • 1Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. Joanna.parkinson@astrazeneca.com.

Journal of pharmacokinetics and pharmacodynamics
|July 27, 2025
PubMed
概括
此摘要是机器生成的。

本教程提供了用于度-QTc (C-QTc) 分析的实用R代码,这是评估药物对QT间隔影响的关键方法. 它详细介绍了准备数据,建模和预测,以准确评估药物安全性.

关键词:
在C-QTc建模中.暴露/反应建模药理动力学/药理动力学在 QT 评估中,QT 评估

更多相关视频

Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0
07:41

Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0

Published on: June 5, 2017

10.0K
Quantifying the Binding Interactions Between CuII and Peptide Residues in the Presence and Absence of Chromophores
11:38

Quantifying the Binding Interactions Between CuII and Peptide Residues in the Presence and Absence of Chromophores

Published on: April 5, 2022

2.6K

相关实验视频

Last Updated: Sep 13, 2025

Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease
09:30

Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease

Published on: December 18, 2016

19.7K
Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0
07:41

Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0

Published on: June 5, 2017

10.0K
Quantifying the Binding Interactions Between CuII and Peptide Residues in the Presence and Absence of Chromophores
11:38

Quantifying the Binding Interactions Between CuII and Peptide Residues in the Presence and Absence of Chromophores

Published on: April 5, 2022

2.6K

科学领域:

  • 药理动力学和药理动力学
  • 临床药理学 临床药理学
  • 生物统计学 生物统计学

背景情况:

  • 度-QTc (C-QTc) 分析是一种基于标准模型的方法,用于评估药物对QT间隔持续时间的影响.
  • 国际协调理事会 (ICH) E14指南和科学白皮书建立了C-QTc建模方法.
  • 实用实施指南和可重复的R代码对于科学家进行这些分析至关重要.

研究的目的:

  • 为推C-QTc建模的实际实施提供实践教程.
  • 为完整的C-QTc分析工作流提供R代码,从数据格式化到模型预测.
  • 用现实世界的数据来说明方法,使用活性治疗和安慰剂.

主要方法:

  • 使用R代码进行数据准备,探索性数据分析和线性混合效应 (LME) 模型拟合.
  • 根据科学白皮书推的C-QTc方法的实施.
  • 估计基线和安慰剂校正的QTc (ΔΔQTc) 的90%置信区间的上限.

主要成果:

  • 该教程展示了使用真实QT研究数据进行C-QTc分析的可重现工作流.
  • 提供的 R 代码有助于进行完整的分析,包括模型性能评估.
  • 该工作流已在制药项目中成功应用,并被监管机构接受.

结论:

  • 本教程为C-QTc分析提供了一个实用指南和可重复的R代码,支持药物安全性评估.
  • 该方法确保准确估计药物诱导的QT间隔变化.
  • 工作流被验证并接受监管提交,帮助科学家进行C-QTc分析.